A Brief Overview of Global Trends in MSC-Based Cell Therapy

Dragomirka Jovic(BGI Group (China)), Yingjia Yu(BGI Group (China)), Dan Wang(University of Chinese Academy of Sciences), Kuixing Wang, Hanbo Li(BGI Group (China)), Fengping Xu(BGI Group (China)), Chenglong Liu, Junnian Liu, Yonglun Luo(BGI Group (China))
Stem Cell Reviews and Reports
March 28, 2022
Cited by 286Open Access
Full Text

Abstract

Human mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells or medicinal signaling cells, are important adult stem cells for regenerative medicine, largely due to their regenerative characteristics such as self-renewal, secretion of trophic factors, and the capability of inducing mesenchymal cell lineages. MSCs also possess homing and trophic properties modulating immune system, influencing microenvironment around damaged tissues and enhancing tissue repair, thus offering a broad perspective in cell-based therapies. Therefore, it is not surprising that MSCs have been the broadly used adult stem cells in clinical trials. To gain better insights into the current applications of MSCs in clinical applications, we perform a comprehensive review of reported data of MSCs clinical trials conducted globally. We summarize the biological effects and mechanisms of action of MSCs, elucidating recent clinical trials phases and findings, highlighting therapeutic effects of MSCs in several representative diseases, including neurological, musculoskeletal diseases and most recent Coronavirus infectious disease. Finally, we also highlight the challenges faced by many clinical trials and propose potential solutions to streamline the use of MSCs in routine clinical applications and regenerative medicine.


Related Papers

No related papers found

Powered by citation graph analysis